Related Experiment Videos
Candida pseudotropicalis fungemia and invasive disease in an immunocompromised patient
Journal of Clinical Microbiology
|November 1, 1984
Abstract:
A case of Candida pseudotropicalis fungemia and invasive disease in an immunocompromised patient is reported. Multiple blood cultures taken over a 2-week period were positive, and histopathological slides of postmortem spleen and kidney tissue showed tissue invasion by the organism. The source of the yeast infection was determined to be the urinary tract. This is the first report of C. pseudotropicalis fungemia documented by culture.
Insights
This case report details Candida pseudotropicalis fungemia in an immunocompromised patient. The urinary tract was identified as the source of this rare yeast infection, confirmed by blood cultures and tissue analysis.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Microbiology
Background:
- Candida pseudotropicalis is a yeast species that can cause opportunistic infections.
- Fungal infections, or fungemia, pose significant risks, especially in immunocompromised individuals.
- Invasive candidiasis requires prompt diagnosis and management.
Observation:
- A case of fungemia and invasive disease caused by Candida pseudotropicalis in an immunocompromised patient.
- Positive blood cultures over a two-week period indicated persistent fungemia.
- Postmortem examination of spleen and kidney tissues revealed invasion by the yeast.
Findings:
- The urinary tract was identified as the primary source of the Candida pseudotropicalis infection.
- This case represents the first documented instance of Candida pseudotropicalis fungemia confirmed by blood cultures.
- Histopathological evidence confirmed systemic invasion by the yeast.
Implications:
- Highlights the potential for Candida pseudotropicalis to cause severe invasive disease.
- Underscores the importance of considering urinary tract infections as a source for systemic candidiasis.
- Emphasizes the need for accurate identification and reporting of rare fungal pathogens in clinical settings.